[192 Pages Report] The Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023 and expected to reach USD 3.72 billion in 2024, at a CAGR 6.37% to reach USD 5.40 billion by 2030.
Diabetic neuropathy is a medical condition that damages the nerve and occurs in patients who have diabetes. High blood sugar (glucose) can damage nerves throughout the body, and diabetic neuropathy most frequently impacts nerves in the legs and feet. The increasing need for effective treatment for diabetic neuropathy, diagnosis of diabetes, and several government initiatives are the major driving factors for the growth of the diabetic neuropathy market. In addition, the growing awareness about diabetic neuropathy, increased healthcare spending, and a rise in pharmaceutical R&D spending contribute to developing novel drugs and systems for treating diabetic neuropathy. However, the high cost of medications used to treat diabetic neuropathy and the availability of alternative therapies may limit their use by diabetic patients. Production of advanced drug delivery systems and rising research in diabetic neuropathy are leading to the development of a breakthrough system for the effective management of diabetic neuropathy conditions, accelerating their use by patients in the forecast period.
The Americas has a significant market in diabetic neuropathy due to the presence of a rising number of diabetic patients and increasing awareness related to diabetes disorders. Approvals from the FDA for new product development and ongoing research activities for developing novel and effective drugs are major growth factors in the Americas region. The Asia-Pacific region represents a growing landscape for the global diabetic neuropathy market due to increasing R&D activities in drug development. Several start-ups focusing on developing diabetic neuropathy treatments in the APAC region have contributed to the market growth. Government support to raise awareness regarding diabetes management and increased research and development of novel drugs and systems for relieving pain and efficient management of diabetic neuropathy conditions are creating the immense potential for the deployment of diabetic neuropathy drugs and systems in the EMEA region. Additionally, the introduction of innovative treatments and drug delivery systems is expected to contribute to the growth of the diabetic neuropathy market worldwide.
Drugs are used in the pharmacological treatment of diabetic neuropathy for alleviating pain and stabilizing nerve function. Pregabalin (Lyrica) and gabapentin (Neurontin) are popular anticonvulsant drugs for managing nerve pain in diabetic neuropathy patients. Among opioids, Tramadol (Ultram) is a centrally-acting opioid analgesic prescribed for moderate to severe pain associated with diabetic neuropathy. Physiotherapy, also known as physical therapy, is a non-pharmacological treatment that can help diabetic neuropathy patients improve their functional abilities and alleviate pain. Regular exercise and strengthening programs supervised by a certified physiotherapist can help improve muscle strength, balance, and endurance in diabetic neuropathy patients. Physiotherapy is often preferred to avoid side effects or contraindications.
Autonomic neuropathy affects the autonomic nervous system, which controls the involuntary functions of internal organs. Patients with this condition experience irregular heartbeat, urinary problems, digestive issues, and sexual dysfunction. Based on individual needs, treatments include medications to regulate blood pressure and heart rate, drugs for gastrointestinal motility, and medications to treat erectile dysfunction. Focal neuropathy is a disorder that affects a single nerve or group of nerves, causing severe pain or weakness localized in specific body parts such as hands, feet, or torso. The treatment addresses the underlying cause, such as compression or entrapment, including splinting or bracing for carpal tunnel syndrome or surgical intervention for severe cases. Peripheral neuropathy is the most common type, affecting the nerves of arms, hands, legs, and feet. Symptoms include numbness, tingling, pain, and weakness. Treatment preferences depend on individual needs, including over-the-counter pain relievers and prescription medications. Proximal neuropathy primarily affects the hip, buttock, or thigh muscles with symptoms such as severe pain and muscle weakness.
Patients with diabetic neuropathy prefer clinics for convenience, affordability, and accessibility as they provide specialized care through a team of experts, including endocrinologists, podiatrists, and diabetes educators. Hospitals serve as comprehensive care providers for diabetic neuropathy patients requiring more extensive treatment or emergency interventions due to severe complications such as infections or ulcers. They offer access to equipment and multidisciplinary teams with expertise in treating complex cases. Online pharmacies have emerged as a convenient distribution channel for medications prescribed for diabetic neuropathy management, such as pain relievers, anti-seizure medications, and antidepressants. Patients prefer online pharmacies due to their ease of use, discreet delivery options, and competitive pricing compared to retail pharmacies. Retail pharmacies are popular for obtaining medications and over-the-counter supplements to manage diabetic neuropathy. They offer the advantage of face-to-face interaction with pharmacists who can provide personalized advice, medication management support, and access to a wide range of products.
The market dynamics represent an ever-changing landscape of the Diabetic Neuropathy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Diabetic Neuropathy Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Diabetic Neuropathy Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Diabetic Neuropathy Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Diabetic Neuropathy Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Diabetic Neuropathy Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Diabetic Neuropathy Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Diabetic Neuropathy Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Diabetic Neuropathy Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Diabetic Neuropathy Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Diabetic Neuropathy Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Diabetic Neuropathy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Diabetic Neuropathy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
NeuraLace Medical, Inc. announced the completion of enrollment in the AT-PDN study, which involved randomizing 70 patients into treatment and sham groups. This development represents a potential breakthrough in the treatment of PDN, with the potential to benefit millions of patients. [Published On: 2023-09-11]
GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
Scientists from the University of Liverpool and Manchester Metropolitan University have received funding of GBP 1.4 million to develop an early test for Diabetic Peripheral Neuropathy (DPN). The project involves collaboration between university investigators and partners such as Aintree University Hospital and Weill Cornell Medicine, funded by the Engineering & Physical Sciences Research Council (EPSRC) for over GBP 1 million. [Published On: 2023-06-07]
Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
Horizon Therapeutics PLC, a biopharmaceutical company focused on creating innovative medicines to enable people to live better lives, received an update from the United States Food and Drug Administration (FDA) regarding the approval of their drug, Tepezza. This drug has already been approved for treating thyroid eye disease and is now considered for treating diabetic neuropathy as well. [Published On: 2023-04-14]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Diabetic Neuropathy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdventHealth, Alkem Labs, Astellas Pharma Inc., AstraZeneca PLC, Bauerfeind AG, Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grünenthal GmbH, Harmonium Pharma s.r.l., Lupin Limited, Medtronic PLC, Merck KGaA, NeuroMetrix, Inc., Nevro Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Praetego, LLC, Regenacy Pharmaceuticals, Inc., Sanofi S.A., Stem Cell Care India, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Trevena, Inc., Vertex Pharmaceuticals Incorporated, Viatris Inc., and Winsantor, Inc..
This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Treatment Type
- Drugs
- Analgesics
- Non-Steroidal Anti-Inflammatory Drugs
- Opioids
- Topical
- Anticonvulsants
- Gabapentin
- Pregabalin
- Topiramate
- Antidepressant
- Serotonin & Norepinephrine Reuptake Inhibitors
- SSRIs
- TCAs
- Analgesics
- Physiotherapy
- Drugs
- Disorder Type
- Autonomic Neuropathy
- Focal Neuropathy
- Peripheral Neuropathy
- Proximal Neuropathy
- Distribution channel
- Clinics
- Hospitals
- Online Pharmacy
- Retail Pharmacy
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Diabetic Neuropathy Market, by Treatment Type
- Diabetic Neuropathy Market, by Disorder Type
- Diabetic Neuropathy Market, by Distribution channel
- Americas Diabetic Neuropathy Market
- Asia-Pacific Diabetic Neuropathy Market
- Europe, Middle East & Africa Diabetic Neuropathy Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 648]
- List of Companies Mentioned [Total: 34]
Diabetic neuropathy, a common complication of diabetes, poses significant challenges to those living with the condition. This debilitating condition arises due to prolonged high blood sugar levels, which damage nerves throughout the body. The result? A symptom that can impact a person's quality of life.
However, in the dynamic world of medical advancements, innovative solutions are emerging to transform the landscape of diabetic neuropathy management. The innovation that's capturing attention is the development of wearable devices equipped with sensors and smart algorithms that can monitor temperature, pressure, and vibration sensation in extremities.
Another groundbreaking avenue lies in the world of regenerative medicine. Researchers are exploring stem cell therapy to repair damaged nerves. Early clinical studies have shown results in improving nerve function and reducing pain. While this area of innovation is still in its infancy, it holds the promise of revolutionizing neuropathy treatment in the future.
Artificial intelligence (AI) is also making its mark in diabetic neuropathy management. AI-powered diagnostic tools can analyze symptoms, medical history, and test results to predict the probability of developing neuropathy.
From wearable sensors to regenerative therapies, the future holds the potential for more effective treatments and enhanced quality of life for those affected by neuropathy.
National Diabetes Prevention Program:
The National Diabetes Prevention Program is an evidence-based lifestyle change program managed by the Centers for Disease Control and Prevention (CDC) that aims to halt the progression of prediabetes to type 2 diabetes by promoting a healthy lifestyle, increasing physical activity, and encouraging healthy eating habits. Patients diagnosed with prediabetes are more likely to develop neuropathy and other complications, and thus, this program can prevent this.
Diabetes Action Plan:
The Diabetes Action Plan is a set of guidelines developed by the US Department of Health and Human Services to improve the management of diabetes and its complications. The plan focuses on educating patients and care providers, improving access to care, and increasing the use of evidence-based practices. This initiative ensures that diabetic neuropathy patients receive the necessary education and healthcare they need to manage their condition effectively.
Medicare Advantage:
In 2021, the Centers for Medicare and Medicaid Services launched the Medicare Advantage Value-Based Insurance Design Model to support Medicare Advantage plans in offering more comprehensive care coverage for patients with chronic conditions like diabetes. This initiative aims to promote value-based care with a focus on outcomes to reduce the burden on patients and improve care quality for those living with diabetic neuropathy.
Diabetes Self-Management Education (DSME) and Support:
DSME is a critical initiative that aims to empower patients with self-management skills to better manage their diabetes and its complications. It is an evidence-based education initiative developed by the CDC that focuses on teaching self-management strategies, promoting healthy lifestyle changes, and encouraging patients to be active participants in their healthcare. DSME empowers diabetic neuropathy patients to take control of their health and well-being.
Telehealth Services:
Finally, during the COVID-19 pandemic, telehealth services have played a vital role in managing diabetic neuropathy. Telehealth services offer remote, secure, and confidential access to healthcare services for patients with diabetes, reducing the risk of exposure to the virus while providing much-needed care. This initiative promotes patient safety, allowing those with diabetic neuropathy to continue receiving necessary healthcare services without the risk of exposure.
The government initiatives for the management of diabetic neuropathy have greatly impacted healthcare outcomes for patients living with diabetes. These initiatives aimed at preventing diabetic neuropathy, empowering patients with self-management skills, and providing much-needed care are vital in managing the condition and reducing its impact. It is essential for healthcare providers, patients, and policymakers to continue to support and invest in these initiatives for better healthcare outcomes for diabetic neuropathy patients.
- How big is the Diabetic Neuropathy Market?
- What is the Diabetic Neuropathy Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?